Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial

Jaguar Health, Inc.

Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
Data presented at ELITE PED-GI Congress; stool volume/frequency reduced and urine output increased, indicating improved oral absorption.
No approved drugs exist for MVID; crofelemer may qualify for EMA PRIME and FDA Breakthrough Therapy programs.
Company supports three investigator-initiated trials and two placebo-controlled Phase 2 studies for MVID/SBS-IF globally.
Additional POC results from IITs expected throughout 2025; early patient access possible in certain EU countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.